Literature DB >> 19506819

Effect of total mesorectal excision on the outcome of rectal cancer after standardized postoperative radiochemotherapy: do randomized studies translate into clinical routine?

Ludwig Keilholz1, Mesud Mese, Klaus Henneking, Jochen Willner.   

Abstract

PURPOSE: To compare local control, disease-free survival and overall survival after postoperative radiochemotherapy with or without total mesorectal excision (TME) in a retrospective analysis. PATIENTS AND METHODS: Between 1993 and 2002, 103 patients with UICC stage II and III rectal cancer were treated by surgery and postoperative chemoradiation. Group B (n = 50; 1993-1998) were operated before TME era without using TME and group A (n = 53; 1998-2002) with TME; both groups received identical radiochemotherapy to a total dose of 50.4 Gy (median) and two courses of continuous 5-fluorouracil infusion.
RESULTS: Patients in group A (TME) showed a significant improvement in 5-year disease-free survival (71.1%; 46.8%) and freedom from distant metastases (76.3%; 46.9%) and a marked improvement of local control (85.2%; 62.5%). Acute and late toxicity were significantly less frequent in group A.
CONCLUSION: Radiochemotherapy cannot compensate an insufficient surgical procedure. These data confirm that TME is the standard. High outcome quality can be achieved in daily practice compared to results of randomized studies without patient selection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19506819     DOI: 10.1007/s00066-009-1940-9

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  25 in total

1.  Total mesorectal excision for surgical treatment of rectal cancer.

Authors:  A Bolognese; M Cardi; I A Muttillo; A Barbarosos; T Bocchetti; S Valabrega
Journal:  J Surg Oncol       Date:  2000-05       Impact factor: 3.454

2.  Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group.

Authors:  K M Tveit; I Guldvog; S Hagen; E Trondsen; T Harbitz; K Nygaard; J B Nilsen; E Wist; E Hannisdal
Journal:  Br J Surg       Date:  1997-08       Impact factor: 6.939

3.  Adaptive RT in rectal cancer: superior to 3D-CRT? A simple question, a complex answer.

Authors:  Karin Haustermans; Sarah Roels; Jan Verstraete; Tom Depuydt; Pieter Slagmolen
Journal:  Strahlenther Onkol       Date:  2007-12       Impact factor: 3.621

4.  Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT).

Authors:  L P Fielding; P A Arsenault; P H Chapuis; O Dent; B Gathright; J D Hardcastle; P Hermanek; J R Jass; R C Newland
Journal:  J Gastroenterol Hepatol       Date:  1991 Jul-Aug       Impact factor: 4.029

5.  Local recurrence following total mesorectal excision for rectal cancer.

Authors:  G Arbman; E Nilsson; O Hallböök; R Sjödahl
Journal:  Br J Surg       Date:  1996-03       Impact factor: 6.939

6.  Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.

Authors:  N Wolmark; H S Wieand; D M Hyams; L Colangelo; N V Dimitrov; E H Romond; M Wexler; D Prager; A B Cruz; P H Gordon; N J Petrelli; M Deutsch; E Mamounas; D L Wickerham; E R Fisher; H Rockette; B Fisher
Journal:  J Natl Cancer Inst       Date:  2000-03-01       Impact factor: 13.506

7.  Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01.

Authors:  B Fisher; N Wolmark; H Rockette; C Redmond; M Deutsch; D L Wickerham; E R Fisher; R Caplan; J Jones; H Lerner
Journal:  J Natl Cancer Inst       Date:  1988-03-02       Impact factor: 13.506

8.  Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer.

Authors:  Valeria Milani; Montserrat Pazos; Rolf Dieter Issels; Veit Buecklein; Sultan Rahman; Katharina Tschoep; Pamela Schaffer; Ralf Wilkowski; Eckhart Duehmke; Moshe Schaffer
Journal:  Strahlenther Onkol       Date:  2008-03       Impact factor: 3.621

9.  Local recurrence following 'curative' surgery for large bowel cancer: I. The overall picture.

Authors:  R K Phillips; R Hittinger; L Blesovsky; J S Fry; L P Fielding
Journal:  Br J Surg       Date:  1984-01       Impact factor: 6.939

10.  The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?

Authors:  R J Heald; E M Husband; R D Ryall
Journal:  Br J Surg       Date:  1982-10       Impact factor: 6.939

View more
  3 in total

1.  Comparison of the micronucleus and chromosome aberration techniques for the documentation of cytogenetic damage in radiochemotherapy-treated patients with rectal cancer.

Authors:  Hendrik Andreas Wolff; Steffen Hennies; Markus Karl Alfred Herrmann; Margret Rave-Fränk; David Eickelmann; Patricia Virsik; Klaus Jung; Markus Schirmer; Michael Ghadimi; Clemens Friedrich Hess; Robert Michael Hermann; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2010-12-23       Impact factor: 3.621

2.  Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.

Authors:  Dietmar Ofner; Alexander F Devries; Renate Schaberl-Moser; Richard Greil; Hans Rabl; Jörg Tschmelitsch; Matthias Zitt; Karin S Kapp; Gerd Fastner; Felix Keil; Wolfgang Eisterer; Robert Jäger; Felix Offner; Michael Gnant; Josef Thaler
Journal:  Strahlenther Onkol       Date:  2011-01-21       Impact factor: 3.621

3.  Intensified preoperative chemoradiation by adding oxaliplatin in locally advanced, primary operable (cT3NxM0) rectal cancer : Impact on long-term outcome. Results of the phase II TAKO 05/ABCSG R‑02 trial.

Authors:  P Kogler; A F DeVries; W Eisterer; J Thaler; L Sölkner; D Öfner
Journal:  Strahlenther Onkol       Date:  2017-11-10       Impact factor: 3.621

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.